Enhancing natural killer cells is beneficial in multiple sclerosis -Commentary
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For almost two decades, it has been speculated that natural killer (NK) cells, a subset of lymphocytes that can trigger the death of virus-infected cells or tumors without priming or antigen recognition, are involved in the regulation of multiple sclerosis (MS). In this issue of the Multiple Sclerosis Journal, Laroni, 1 Liu, and Shi 2 discuss the evidence supporting or challenging that contention. A number of studies published in the 1980s found a reduced cytotoxic activity, and/or frequency, of circulating NK cells in individuals with MS compared with age and sex matched controls. 3, 4 At that time chronic viral infection (particularly measles) had been implicated in MS pathogenesis, and it was speculated that NK cell dysfunction might permit the persistence of viruses in the central nervous system (CNS), ultimately culminating in inflammatory demyelination. Since then, the hypothesis that MS lesion formation is driven by an active infection has largely been discounted in favor of an autoimmune etiology. This raises the question of whether NK cells directly modulate encephalitogenic leukocytes. In fact, targeted depletion of NK cells exacerbates experimental autoimmune encephalomyelitis (EAE). 5, 6 Ex vivo experiments demonstrate that NK cells are capable of modulating or killing myelinprimed lymph node cells, antigen-presenting cells, and pathogenic monocytes. 5, [7] [8] [9] As underscored in the commentary by Dr Laroni, an interest in NK cells as regulators of the human disease was rekindled by mechanistic substudies of MS clinical trials that revealed an association between the therapeutic efficacy of disease-modifying therapies (DMTs), or autologous hematopoietic stem cell transplantation, and the expansion of circulating NK cells. 7, [10] [11] [12] [13] Of particular interest is a CD56 bright subset of NK cells that were first found to accumulate in the blood of MS patients treated with daclizumab, and subsequently in patients treated with alemtuzumab or dimethyl fumarate. [10] [11] [12] While compelling, these studies do not definitively distinguish between whether NK cell expansion plays a causative role in MS disease suppression or represents an epiphenomenon. In fact, CD56 high NK cell
